Abstract. Inflammation mediated by activated microglia cells has been shown to contribute to the pathogenesis of Alzheimer disease (AD) [1] . Microglia are the immune cells in the central nervous system, and when activated they secrete the lipid-derived mediator prostaglandin E2 (PGE2), the cytokine interleukin-1β (IL-1β), and other inflammatory mediators. Apolipoprotein E isoform 4 (apoE4), coded for by the gene APOE4 (ε4), has been shown to correlate with higher risk of onset of AD, as well as with increased severity of other diseases with a neuroinflammatory component. This study investigated isoform-specific effects of apoE on the regulation of PGE2, COX2, and IL-1β expression. Two physiologically relevant preparations of apoE displayed an isoform-specific effect on inflammation in primary adult microglia cultured from adult rat brain cortex. Specifically, apoE4 alone, but not the more common isoform apoE3, stimulated secretion of PGE2 and IL-1β. The increase in PGE2 release stimulated by apoE4 was not accompanied by the upregulation of the COX-2 enzyme in microglia.
Introduction
Apolipoprotein E (apoE), a 299 amino acid protein (34 kD) , is a plasma glycoprotein that binds to cholesterol and other lipids, forming lipoproteins. The primary apoE-containing lipoproteins are HDL (high density lipoprotein) and VLDL (very low density lipoprotein). There are three alleles of human gene APOE at a single gene locus on the proximal long arm of chromosome 19q13. 2 [50] .
APOE3 is the most common (85% of alleles), APOE4 the second (12%) and APOE2 the least (3%) [14, 51, 66, 72] . ApoE in the brain is synthesized by glial cells, predominantly by astrocytes [12, 64] , and by microglia [61, 80] . Brain apoE is found predominantly in an HDL-like lipoprotein [45, 46] . Thus, major functions for apoE in CNS may be mediating lipid transport and membrane maintenance [26, 65, 66, 71] . For over a decade, the allele ε4 (APOE4) has been known to be the single strongest risk factor for Alzheimer disease (AD), and it correlates with an earlier age of onset and increased incidence of familial and sporadic AD [73, 74, 81] . APOE4 gene dosage correlates with density of amyloid plaques in brain tissue [43, 55, 63, 67, 74] and the number of activated microglia in frontal and temporal cortices in AD brains, which in-creased significantly with APOE4 gene dose [24] .
In vivo, the presence of the APOE4 gene is associated with the activation of microglia [17, 48] . In vitro, apoE3 but not apoE4 reduced nitric oxide production [34] . An in vitro study of mixed astrocyte and microglia cultures found both apoE3 and apoE4 to exert both anti-inflammatory and pro-inflammatory influences, depending on circumstances, but apoE4 had far greater pro-inflammatory effect in increasing IL-1β secretion than apoE3 [32] . The evidence that apoE4 tends to be pro-inflammatory compared to apoE3 suggests that inflammatory mechanisms may contribute to the association of apoE4 with AD. However, no published study has tested apoE4 as a direct activator of primary microglia in culture, particularly in adult cells.
Inflammation has been shown to contribute to the pathogenesis of AD; activated microglia are the major cell mediator in inflammatory processes in AD [1] . Many inflammation-related molecules have been identified in AD brains [1, 31, 70] , and PGE2 has been shown to be elevated in CSF [59] . Epidemiological studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) prevent or delay the initial onset of AD symptoms [4, 5, 13, 15, 39, 49, 54, 68, 69, 79] . Although the mechanism by which NSAIDs delay AD is not known yet, the principle pharmacological activity of NSAIDs is to inhibit cyclooxygenases (COX), COX-1 and COX-2, responsible for the conversion of arachidonic acid into prostanoids, including PGE2 [58, 83] . The efficacy of NSAIDs to reduce the risk for AD leads to the hypothesis that prostaglandin production in brain promotes the inflammatory processes in AD. For this reason, the aim of the present work was to understand whether apoE4, the gene product of a genetic risk factor, could trigger PGE2 secretion and COX-2 expression from microglia.
Secretion of IL-1β by activated microglia has been implicated in many neuropathological scenarios, including AD [3, 22, 30, 75] . Because IL-1β is a general marker for immune activation, its study may help to determine whether PGE2 release is part of a broader activation response in microglia. In this study, we investigated the isoform-specific effect of two physiologically relevant preparations of apoE on secretion of both PGE2 and IL-1β in primary adult rat microglia culture.
Materials and methods

Adult rat microglia culture
Primary adult cortical microglial cultures were established from 10-13 week old Sprague Dawley rats by a modification of previous methods [56, 77] . In brief, the cortices were dissected free of meninges and blood vessels, and minced in 2.5 ml cold 0.2% trypsin with 0.005% DNAse I (both from Sigma Aldrich). The minced tissue was incubated on a platform shaker at 80 to 85 oscillations per minute at 37
• C for 80 minutes. The tissue from each brain was triturated and sieved through 15 µm pore size nitex filter. The sieved tissue was centrifuged twice in L-15 with 26% Percoll (Sigma) at 500 g for 20 minutes. The cell pellet was resuspended in L-15, and then centrifuged at 500 g for 14 minutes. The cell pellet was then resuspended in the culture medium previously described [6] , based on Bottenstein [11] and Michler-Stuke et al. [57] , with 10% heat-inactivated fetal bovine serum (FBS) and penicillin-streptomycin added. The cell suspensions, typically 2-3 × 10 6 cells, were plated on uncoated glass coverslips (12 mm diameter) in a 24-well plate at 2 × 10 5 cells in 100 µl per coverslip. The cultures were incubated exactly 50 minutes at 37
• C in a humidified container with 5% CO 2 , then flooded with 5-6 drops of culture medium with 10% FBS. Microglia adhered to the coverslips while oligodendrocytes and other non-microglial cells were detached by shaking the plate. Fresh medium was replaced, and incubation was resumed. The medium was changed the next day and replaced every 2-3 days. Experimental incubations were carried out for a period of 18-20 hours in a volume of 360 µl of culture medium per well, with or without 5% FBS, in a humidified incubator. The purity of microglia culture was 98%, verified by immunostaining with microglia antigenic marker OX-42, which binds to the complement receptor CR-3b on the microglia surface.
ApoE treatment
Experimental treatments were added to duplicate wells on day four, five, or six, at the point when cells in the centers of the culture wells became confluent. Incubation medium contained apoE3 or apoE4 and 5% FBS. Culture medium with 5% FBS was added to negative control wells; LPS (50 ng/ml) with 5% FBS was added to positive control wells. Every experiment included both negative and positive controls. Cells were incubated for a period of 18 to 20 hours at 37
• C. Cell survival after each treatment was examined by analyzing cell morphology by phase contrast microscopy. The concentration of apoE used in this study, 50 µg/ml or approximately 1.5 µM, is within the physiological range of concentration of apoE in plasma, reported to be 37-57 µg/ml [76] . A lower concentration of apoE, 5 µg/ml or 0.15 µM, was also tested; this is close to the concentration range of apoE in cerebrospinal fluid, reported as 1-7 µg/ml [36] .
Assays
PGE2 secretion by microglial cells was measured by a specific sandwich enzyme-immunoassay (ELISA) (Amersham Pharmacia Biotech) of fresh culture supernatants after 18-20 hours of incubation with experimental treatments. IL-1β secretion by microglial cells was measured from the thawed frozen samples of culture supernatants by Quantikine M rat IL-1β kit (R&D Systems). Protein content of the cells in each well was measured by bicinchoninic acid (BCA) protein assay kit (Pierce). The final level of PGE2 and IL-1β secretion from each culture well was expressed as PGE2 or IL-1β (pg) per µg protein.
Immunostaining
The presence of COX-2 enzyme was detected by goat polyclonal antibody to COX-2 (Santa Cruz Biotechnology) diluted 1:200. Cells were incubated in primary antibody for 1 hour at room temperature. The secondary antibody for anti-COX-2 was tetramethyl-rhodamine isothiocyanate-conjugated donkey anti-goat IgG (Jackson Immunoresearch) diluted 1:100. The cells were incubated for 1 hour in secondary antibody. Immunofluorescence was evaluated using a Leica DM-RX fluorescence microscope. As a negative control, the secondary antibody was applied without primary antibody for evaluation of anti-COX-2 immunostaining. The percentage of COX-2 positive cells was calculated by counting 200-300 cells from 5-6 sample fields per coverslip under fluorescent microscopy (40X objective). The experiments were carried out in duplicate and the results were averaged for each treatment in each independent experiment. Two observers together established a standard for the anti-COX-2 positive cells. The observer counting the cells was blind to the treatments added to the cultures.
Statistical analysis
Data were analyzed by One Way Repeated Measures Analysis of Variance calculated by Sigma Stat software version 1.03 (Jandel Scientific), followed by post hoc comparisons of means with Dunnett's test for multiple comparisons. p value < 0.05 was considered statistically significant. Data presented are means ± standard error of the mean (SEM) from at least three independent experiments.
Materials
ApoE3 and E4 were isolated in the laboratory of Dr. M.J. LaDu from the serum-free conditioned media of human embryonic kidney (HEK)-293 cells stably transfected with cDNA encoding human apoE3 or apoE4. The HEK-apoE particles were isolated by size exclusion chromatography (SEC) using tandem superose 6 columns with PBS as the mobile phase. Isolation by SEC indicated that the apoE eluted in fractions consistent with an HDL-2 sized particle (HEK-apoE). Before addition to cultures, apoE3 and apoE4 were aseptically dialyzed in 300 ml of sterile 1:1 DMEM: HAM's F-12 medium in gamma irradiated dialysis cassettes (Pierce) for one hour. The concentrations of stock apoE ranged from 6.2 to 18 µM. The final concentration of apoE3 or apoE4 in incubation medium was 1.5 µM (in most of the experiments) and 3 µM (in two experiments). Thus, both the apoE particles and concentration used were physiologically relevant.
Commercial recombinant apoE3 and apoE4 (RecapoE) were obtained from Calbiochem at a concentration of 0.39 mg/ml in liquid 700 mM NH 4 HCO 3 , pH 7.5. The recombinant apoE in NH 4 HCO 3 was aseptically dialyzed against sterile 1:1 DMEM: Ham's F-12 and used at a final concentration of 1.2 µM (39.3-40 µg/ml) in microglia incubation medium.
HDL prepared from pooled human plasma was purchased as a liquid stock solution at 16-20 mg/ml in buffered saline from Sigma Aldrich (product L-8039) or Intracel (product RP-035). Because plasma from over 30 donors is used to prepare each batch of HDL, presumably the native apoE present is mostly apoE3 with some apoE4 included. The final concentration of HDL protein in incubation medium was 200 µg/ml; no more than 3% of this amount represents apoE, so that the amount of apoE added with HDL was no more than 6 µg/ml, compared to 50 µg/ml recombinant apoE3 or apoE4. The HDL added to incubation medium was approximately three times the normal plasma concentration of HDL (about 70 µg/ml). It is doubtful whether this amount of HDL was needed to support the exogenous apoE4 activity (for example, 1 µM apoE4 was active with 50-100 µg/ml HDL in stimulating microglial uptake of amyloid beta-protein [20] ). Rather, the concentration was chosen to optimize dialysis conditions for commercial apoE (above). HDL was added to apoE in 700 mM NH 4 HCO 3 before dialysis as a safeguard against apoE sticking to the dialysis membrane. After one hour, a second addition of HDL with culture medium was made, and a further one hour period was Fig. 1 . Stimulation of PGE2 secretion by addition of apoE4 (1.5 µM) to microglial cultures. Neither apoE3 (1.5 µM) nor the control medium stimulated a measurable release of PGE2. Cultures were incubated 18-20 hrs in medium containing 5% FBS, with or without apoE, and PGE2 was measured by ELISA and normalized to protein for each well. ApoE4 result was significantly different from control, p < 0.05. Data presented are means ± SEM (n =3 independent experiments).. allowed for binding of apoE to HDL before carrying out the dialysis.
Lipopolysaccharide (LPS) from E coli (serotype 055: B5, Sigma product L-6529) was used as an activator of microglia and a positive control. LPS has been widely used as an activator of microglia and macrophages in studies of inflammation. Some modulators of inflammation alter the responses of activated microglia and macrophages to LPS, without eliciting detectable responses on their own. Here, LPS was used as a positive control within each independent experiment. LPS was dissolved at a concentration of 2 µg/µl in culture medium and frozen in aliquots at −80
• C. The aliquots were thawed and diluted in medium immediately before addition to the cultures. The LPS solution was diluted and sonicated for 15 seconds by 550 Sonic Dismembrator (Fisher Scientific) for a more even suspension. The final concentration of LPS was 50 ng/ml.
Results
HEK-apoE4 (1.5 µM) dramatically enhanced PGE2 secretion in microglia compared to negative controls in the presence of 5% FBS, whereas apoE3 (1.5 µM) had no measurable effect (Fig. 1) . In the serum-alone control, PGE2 secretion was low, ranging from 0 to 1 pg/µg protein, the lower limit of detection of the assay according to the manufacturer. In the apoE4 group, PGE2 secretion ranged from 14 to 35 pg/µg protein, whereas in the apoE3 group, the PGE2 secretion ranged from 0 to 3 pg/µg protein.
To determine whether the increase in PGE2 was the result of increased COX-2, the percentage of COX-2 immunoreactive cells in microglial cultures was calculated using indirect immunostaining. Immunofluorescence was evaluated microscopically; anti-COX-2 positive cells had a bright red rhodamine color, whereas negative cells were dim ( Fig. 2A) . No increased immunoreactivity of COX-2 was seen in microglia incubated with either HEK-apoE4 (Fig. 2) or HEKapoE3 (data not shown) with FBS, compared to control medium, although increased PGE2 was released from microglia incubated with apoE4, as measured by ELISA. In cultures treated with HEK-apoE4 (Fig. 2B) , the percentage of anti-COX-2 positive cells was 0-1%, whereas the percentage of anti-COX-2 positive cells in the LPS group was 18 ± 3% (Fig. 2B) . Thus, the induction of PGE2 by apoE4 appeared not to be mediated by upregulation of COX-2.
Because most apoE in circulation is bound to lipoprotein, we tested whether human HDL could substitute for HEK-apoE in FBS in facilitating apoE4 stimulation of microglial PGE2 secretion. Commercial human recombinant apoE4 (Rec-apoE4, 1.2 µM) and HDL (200 µg/ml) from pooled human plasma, applied to microglial cultures in serum-free incubation medium for 18-20 hrs, significantly increased PGE2 secretion (Fig. 3) , while HDL alone at the same concentration had no significant effect. Recombinant apoE3 (1.2 µM) with HDL (200 µg/ml) was also tested and found to have no significant effect on microglial PGE2 secretion. Therefore, human HDL is an adequate substitute for HEK-apoE in FBS for facilitating the effect of apoE4 on microglial PGE2 secretion.
To determine whether apoE4-stimulated PGE2 release is part of a broader activation response in microglia, IL-1β secretion was tested under the same experimental conditions. HEK-apoE4 (1.5 µM) in the presence of FBS dramatically enhanced IL-1β secretion in microglia compared to negative control, whereas apoE3 (1.5 µM) had no measurable effect (Fig. 4) .
To test whether the presence of HDL or FBS contributed to the stimulatory effect of apoE4, experiments were repeated under the same conditions in the absence of either HDL or FBS. Neither apoE4 (1.5 µM) nor apoE3 (1.5 µM) stimulated microglial PGE2 or IL-1β secretion in serum-free medium. However, LPS (50 ng/ml) did stimulate both PGE2 and IL-1β secretion in serum-free, HDL-free medium, showing that the cultured cells were capable of activation in the absence of added serum or lipoprotein. Fig. 3 . Effect of commercially prepared recombinant apoE4 (1.2 µM) with pooled human HDL (200 µg/ml). This combination was approximately equal in stimulating microglial PGE2 release to apoE4 purified in the LaDu lab and 5% FBS (Fig. 1) . A small, insignificant effect of HDL alone is recorded. ApoE4 stimulation was significantly different from control and from HDL alone, p < 0.05. Data presented are means of 3 independent experiments.
Discussion
We have demonstrated that apoE4, but not the apoE3 isoform, in the presence of lipoprotein HDL or serum, stimulates an inflammatory response in microglia. Important features of these experiments were the use of primary adult microglia from cerebral cortex of rat, use of two physiologically relevant preparations of apoE with lipids, and the finding that both PGE2 and IL-1β secretion were stimulated, indicating that apoE4 elicits both lipid and cytokine mediators of inflammation.
Accumulating evidence suggests that inflammatory mechanisms are involved in the pathogenesis of AD. The efficacy of nonsteroidal anti-inflammatory drugs to prevent AD [4, 5, 13, 15, 39, 49, 54, 68, 69, 79] led us to the hypothesis that prostaglandin production in brain may promote the inflammatory processes in AD. A potential mechanism for PGE2 involvement in CNS inflammation and neurodegeneration has been suggested by Bezzi et al. [10] based on their studies of the astrocytic role in glutamate neurotoxicity. In co-culture with neurons, astrocytes stimulated with TNF-α release glutamate. Including microglia in the co-cultures resulted in approximately a 10-fold increase in glutamate and an even greater increase in neuronal death. Studies with prostaglandin receptor inhibitors showed the increase in glutamate release was attributable to stimulation of astrocytes by microglial PGE2 in a cascade arrangement with TNF-α.
For over a decade, the allele ε4 (APOE4) has been known to correlate with higher risk and earlier age of onset of AD [73, 74, 81] ; however, no mechanism for the association has been known. The isoform specific effect of apoE on activating microglia suggests that the association of AD with apoE4 may be caused by inflammatory mechanisms [7, 17, 21, 24, 48] . Until now, little has been known about how apoE4 protein itself might activate microglia or modulate the activation of microglia. Although it has been suggested that the amount of apoE circulating in brain and cerebrospinal fluid varies according to APOE genotype, evidence for this idea is conflicting, with different authors finding that apoE concentration is less [9] , the same [33] , or more [36] in individuals carrying the APOE4 allele.
To our knowledge, the present study is the first to show that apoE4 itself, but not apoE3, activates adult rat microglia and induces the release of inflammatory mediators PGE2 and IL-1β in vitro. This isoform specific effect of apoE on microglial activation is in agreement with previous studies that have shown an isoform specific effect of apoE on the microglial response to inflammatory stimulation. Barger and Harmon [7] demonstrated that apoE3, not apoE4, inhibited nitrite secretion stimulated by amyloid precursor protein in N9 mouse microglial cell line. Guo et al. [32] found that apoE4, much more than apoE3, stimulated IL-1β secretion from cultures of mixed glia containing 5% microglia and 95% astrocytes from neonatal rat cerebral cortex. Whereas the pro-inflammatory function of apoE was strongly associated with apoE4, this study also found both apoE3 and apoE4 to have anti-inflammatory functions in modulating the mixed glia activation in response to amyloid β-protein.
In addition to the studies of apoE protein, several studies have demonstrated that the presence of APOE4 gene is associated with increased activation of mi-croglia. Lombardi et al. [48] showed that AD sera, mainly in the APOE 3/4 and 4/4 genotypes, increased the ameboid cell number, MHC II antigen expression, and IL-1β release in neonatal rat microglia, compared to AD sera in the APOE 2/3 genotype. Egensperger et al. [24] showed a significant correlation between the number of activated microglia in frontal and temporal cortices in AD brains with APOE4 gene dosage. Furthermore, macrophage studies demonstrated that nitric oxide production increased in macrophages from APOE4 transgenic mice compared to APOE3 transgenic mice [17, 21] . Although the mechanisms underlying the isoform specific difference of apoE or APOE genotype are not known yet, these studies strongly suggest that the presence of apoE4 in senile plaques in AD brains could be a direct stimulus that exaggerates the inflammatory response in AD brains.
The isoform specific stimulatory effect of apoE4 in the present studies depended upon the presence of either HDL or 5% serum, whereas purified apoE4 in serum-free medium did not increase PGE2 and IL-1β secretion. Substitution of FBS with HDL suggests that lipoprotein, as a carrier for apoE, may be the active component of serum in these experiments. To be active, apoE must be in a conformation that is usually imposed by the presence of lipids. The HEK-secreted apoE particles are lipid poor, and may therefore require a source of lipid in the incubation medium to achieve their full function. Commercial recombinant apoE is supplied lipid-free, thus also requires the addition of lipid or lipoprotein.
The stimulatory effect of apoE4 could be mediated by apoE receptors. Several apoE receptors have been found on microglia, such as LDL-R, AcLDL-R [16, 29] , VLDL-R [19] , and LRP [52] . With some exceptions, apoE acts as a ligand for apoE receptors only when it is particle-associated; purified apoE generally does not bind to its receptors [41] . One recently discovered exception is that LRP receptor binds and mediates degradation of lipid-poor apoE, while LDL-R has little efficacy for degradation of lipid-poor apoE [62] . It may be that the addition of lipid to apoE particles changes the pattern of apoE targeting among the several receptors present on microglia. In the present study, lipoprotein or FBS may provide lipids that are required for receptor binding for apoE [40, 42] or for targeting of apoE to a receptor that mediates inflammatory activation. Further study is needed to elucidate whether the effect of apoE4 on PGE2 and IL-1β secretion is mediated by apoE receptors on microglia. Although the role of receptor binding in PGE2 and IL-1β secretion in microglia is not clearly known, Herz et al. [35] suggested that the members of LDL-R family can mediate intracellular signal transduction by interacting with cytoplasmic adaptor and scaffold proteins [35, 47] . ApoE might be tested in competition with the LDL/LRP receptor antagonist receptor-associated protein (RAP) or other lipoprotein receptor competitors such as fucoidan, alpha-2-macroglobulin and acetylated LDL.
To test whether increased PGE2 secretion was mediated by COX-2, immunocytochemistry was used to evaluate COX-2 expression in culture. The results showed that the percentage of anti-COX-2 positive cells was not increased by apoE4 in microglia compared to the negative control. Possibly the induction of PGE2 secretion by apoE4 was mediated by COX-1, rather than by COX-2. COX-1 expression, though not COX-2, has been found in microglia associated with senile plaques in AD [37, 85] . ApoE4 may directly induce increased arachidonic acid release, which then increases PGE2 secretion via COX-1 activity in a dose-dependent manner in human microglia [38] . Future studies using COX-1 specific inhibitor and measuring arachidonic acid production are needed to ascertain whether COX-1 and increased arachidonic acid mediate the PGE2 secretion stimulated by apoE4 in microglia. Although the measurement of COX-2 in microglia by immunostaining may be insufficiently sensitive to visualize a difference in the expression of this enzyme under apoE4 stimulation, it does show robustly increased anti-COX-2 immunolabeling in response to LPS stimulation.
These results demonstrate that a common protein isoform (apoE4) stimulates an immune response. This activity may partly explain the reported exacerbation of neurodegenerative diseases with an inflammatory component in patients carrying an APOE ε4 allele. APOE4 is a major risk factor for poor clinical outcome after hemorrhagic stroke [2, 53, 84] and traumatic head injury [28, 44, 78, 82] . Several studies indicated an association of the APOE ε4 allele with a more severe course of multiple sclerosis [8, 18, 25, 27] and amyotrophic lateral sclerosis [23, 60] . However, the underlying mechanisms of the association of APOE4 with both acute and chronic neurological diseases are not yet clearly known.
In conclusion, the primary finding in this study is that apoE4 can stimulate adult rat microglia to secrete PGE2 and IL-1β in vitro in the presence of HDL or serum. The isoform specific effects of apoE on PGE2 and IL-1β secretion in microglia suggest that the association of apoE4 with AD may be caused by inflammatory mechanisms. Similarly, apoE4 may be an exac-erbating factor in other neurological diseases that have an inflammatory component. The study suggests that apoE4 may act as an activator of microglia, triggering a neuroinflammatory response that potentially results in astrocyte activation and neuronal damage. Interestingly, apoE4-stimulated microglia secreted PGE2 but without upregulation of COX-2, in agreement with neuropathological findings that COX-2 is absent from microglia in senile plaques and with clinical trials indicating that COX-2-specific inhibitors are not effective against Alzheimer disease.
